Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5900488 | BAUSCH | Method for treating mycosis using imidazolylacetonitrile derivatives |
Jan, 2020
(4 years ago) | |
US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(9 years from now) | |
US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(9 years from now) | |
US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(10 years from now) |
Luzu is owned by Bausch.
Luzu contains Luliconazole.
Luzu has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Luzu are:
Luzu was authorised for market use on 14 November, 2013.
Luzu is available in cream;topical dosage forms.
Luzu can be used as treatment of fungal infections.
Drug patent challenges can be filed against Luzu from 14 November, 2017.
The generics of Luzu are possible to be released after 28 April, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using
LULICONAZOLE ingredient